Frencken Group's Likely Revenue Growth in 1H May Outperform Industry -- Market Talk

Dow Jones
05/26

0151 GMT - Frencken Group's likely revenue growth in 1H, driven by its semiconductor and medical segments, may outperform the industry, UOB Kay Hian's John Cheong says in a research report. The technology solutions provider has a cautiously optimistic stance and expects moderate revenue growth in 1H 2025 versus 2H 2024, the analyst notes. The Singapore-listed company also doesn't expect significant impact from U.S. tariffs, given shipments to the U.S. accounted for only around 9% of its revenue in 2024. The brokerage lifts its price-to-earnings multiple peg to 15x from 12.5x to reflect Frencken's ability to outperform peers. It raises the stock's target price to S$1.40 from S$1.16 with an unchanged buy rating. Shares are unchanged at S$1.13. (ronnie.harui@wsj.com)

 

(END) Dow Jones Newswires

May 25, 2025 21:51 ET (01:51 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10